Advertisement

Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review

  • Döndü Üsküdar CansuEmail author
  • Ezgi Demirtaş
  • Neslihan Andiç
  • Hava Üsküdar Teke
  • Cengiz Korkmaz
Case Based Review
  • 41 Downloads

Abstract

Tocilizumab (TCZ) may rarely cause hematological side effects including neutropenia and thrombocytopenia. TCZ is essentially expected to lower the fibrinogen levels to stay within the normal range, but TCZ-induced hypofibrinogenemia has been rarely reported in literature. Although it may remain asymptomatic, hypofibrinogenemia has clinical significance owing to the tendency of the condition to result in bleeding. A 65-year-old female patient with known polymyositis was, approximately 20 years after the diagnosis was made, examined due to elevated acute phase reactants leading to the diagnosis of giant cell arteritis (GCA) and TCZ treatment was initiated as she had former steroid-induced osteoporotic fractures. 1 month after the initial dose of intravenous (IV) TCZ, she presented with ecchymosis and was detected to have hypofibrinogenemia. Following the administration of the second dose, hypofibrinogenemia was detected again. In this review, we have analyzed this patient in addition to the cases in six other articles of TCZ induced hypofibrinogenemia which we found out based on our search strategy. Our aim is to point out a rare side effect of TCZ, hypofibrinogenemia, thus to emphasize a possible bleeding disorder and discuss probable underlying mechanisms.

Keywords

Tocilizumab Hypofibrinogenemia Fibrinogen level Bleeding 

Notes

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from our patient included in the study.

References

  1. 1.
    Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 77:1865–1879CrossRefGoogle Scholar
  2. 2.
    Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13:R141CrossRefGoogle Scholar
  3. 3.
    Martis N, Chirio D, Queyrel-Moranne V, Zenut MC, Rocher F, Fuzibet JG (2017) Tocilizumab-induced hypofibrinogenemia: a report of 7 cases. Jt Bone Spine 84:369–370CrossRefGoogle Scholar
  4. 4.
    Vitiello G, Orsi Battaglini C, Radice A, Carli G, Micheli S, Cammelli D (2017) Sustained tocilizumab-induced hypofibrinogenemia and thrombocytopenia. comment on: “Tocilizumab-induced hypofibrinogenemia: a report of 7 cases” by Martis et al. Jt Bone Spine 84:649–650CrossRefGoogle Scholar
  5. 5.
    Matsuoka M, Majima T, Onodera T, Ieko M, Souri M, Ichinose A, Kurita T, Kasahara Y, Inoue M, Takahashi D (2012) Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis. Int J Hematol 96:781–785CrossRefGoogle Scholar
  6. 6.
    Imamura H, Momohara S, Yano K, Sakuma Y, Nakayama M, Tobimatsu H, Ikari K (2018) Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty. Mod Rheumatol 28:976–980CrossRefGoogle Scholar
  7. 7.
    Souri M, Mokuda S, Inanami H, Osaki T, Takasugi K, Ichinose A (2016) Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab). Thromb Res 140:100–105CrossRefGoogle Scholar
  8. 8.
    Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S, Koike T, Nakamura H (2016) Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int 36:349–357CrossRefGoogle Scholar
  9. 9.
    Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRefGoogle Scholar
  10. 10.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of Internal Medicine, School of MedicineEskişehir Osmangazi UniversityEskisehirTurkey
  2. 2.Department of Internal MedicineEskişehir Osmangazi UniversityEskisehirTurkey
  3. 3.Division of Hematology, Department of Internal MedicineEskişehir Osmangazi UniversityEskisehirTurkey
  4. 4.Division of Rheumatology, Department of Internal MedicineEskişehir Osmangazi UniversityEskisehirTurkey

Personalised recommendations